Hepatocellular carcinoma in Budd-Chiari syndrome: A single center experience with long-term follow-up in South Korea

Table 1 Baseline clinical characteristics of patients with Budd-Chiari syndrome (n = 67)

Characteristics	Budd-Chiari syndrome
Age (yr)	47 ± 16
Gender (male)	34 (50.7)
Obstruction site
IVC	56 (83.6)
Hepatic vein	5 (7.5)
Combined	6 (9.0)
Alcohol consumption
None/social/heavy (> 80 g/d)	32 (47.8)/15 (22.3)/20 (29.9)
Positive viral marker
HBsAg/anti-HCV	3 (4.5)/0 (0)
Liver cirrhosis at diagnosis	54 (80.6)
Child-Pugh A/B/C	25/23/6 (37.3/34.3/9.0)
MELD score	11 ± 6
Decompensate LC symptoms	23 (34.3)
Length of obstruction (cm)	2.0 ± 4.0
HVPG (mmHg)	15 ± 10
Laboratory data
ALT (IU/L)	19 ± 17
Bilirubin (mg/dL)	1.4 ± 1.3
Albumin (g/dL)	3.8 ± 0.7
Hemoglobin (g/dL)	12.3 ± 2.6
Platelet count (k/μL)	109 ± 78
Creatinine (mg/dL)	0.9 ± 0.2
PT (%)	73 ± 27
Treatment modality
Angioplasty	27 (40.3)
Shunt operation	4 (5.9)
TIPS	3 (4.5)
Thrombolysis	1 (1.5)
Symptomatic medical treatment	32 (47.7)
Median follow up period (mo)	103 ± 156

Data were expressed as median ± IQR or n (%). IVC: Inferior vena cava; HCV: Hepatitis C virus; HbsAg: Hepatitis B surface antigen; MELD: Model for End-Stage Liver Disease; LC: Liver cirrhosis; HVPG: Hepatic venous pressure gradient; ALT: Alanine aminotransferase; PT: Prothrombin time; TIPS: Transjugular intrahepatic portosystemic shunt; IQR: Interquartile range.